StreetInsider.com News Articles

DiaMedica Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Fri, 17 Jul 2026 16:30:00 -0400

MINNEAPOLIS--(BUSINESS WIRE)-- DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction and acute ischemic stroke, today announced that on July 15, 2026, it granted options to purchase an aggregate of 160,000 shares of DiaMedica’s common stock to a newly hired non-executive employee whose employment commenced in July 2026. The stock options were a material inducement to the employee’s acceptance of employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4) as a component of their compensation.

The stock options were approved by the Compensation Committee of the

DiaMedica Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Fri, 17 Jul 2026 16:30:00 -0400

The stock options were approved by the Compensation Committee of the

DiaMedica Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Fri, 17 Jul 2026 16:30:00 -0400

The stock options were approved by the Compensation Committee of the

DiaMedica Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Fri, 17 Jul 2026 16:30:00 -0400

The stock options were approved by the Compensation Committee of the

DiaMedica doses first patients in Phase 2 fetal growth restriction trial

Tue, 23 Jun 2026 08:30:31 -0400

DiaMedica Therapeutics Inc. (NASDAQ: DMAC) has dosed the first two patients in an investigator-sponsored Phase 2 trial evaluating DM199 (rinvecalinase alfa) for the treatment of fetal growth restriction (FGR), according to a company statement.

The open-label, single-arm study is designed to evaluate three dose levels of DM199 in up to 30 patients with early-onset FGR between 27 and 32 weeks of gestation. The primary objective is to assess safety and tolerability. Exploratory efficacy endpoints include uterine artery vascular resistance, umbilical artery Doppler findings, fetal growth trajectory, birthweight, pregnancy prolongation, and DM199 levels in umbilical cord blood at birth.

FGR affects approximately 10%

DiaMedica doses first patients in Phase 2 fetal growth restriction trial

Tue, 23 Jun 2026 08:30:31 -0400

FGR affects approximately 10%

DiaMedica Therapeutics Announces First Patients Dosed in Phase 2 Trial of DM199 for the Treatment of Fetal Growth Restriction

Tue, 23 Jun 2026 08:30:00 -0400

First clinical evaluation of DM199 (rinvecalinase alfa) in fetal growth restriction, a leading cause of stillbirth with no approved pharmacologic treatment
DM199 is intended to improve maternal uterine artery blood flow to the placenta without crossing into fetal circulation
Fetal Growth Restriction white paper authored by leading maternal-fetal medicine experts released

MINNEAPOLIS--(BUSINESS WIRE)-- DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company developing novel treatments for preeclampsia, fetal growth restriction and acute ischemic stroke, today announced the dosing of the first two patients in an investigator-sponsored Phase 2 trial evaluating DM199 (rinvecalinase alfa) for the treatment of fetal growth

DiaMedica Therapeutics Announces First Patients Dosed in Phase 2 Trial of DM199 for the Treatment of Fetal Growth Restriction

Tue, 23 Jun 2026 08:30:00 -0400

First clinical evaluation of DM199 (rinvecalinase alfa) in fetal growth restriction, a leading cause of stillbirth with no approved pharmacologic treatment
DM199 is intended to improve maternal uterine artery blood flow to the placenta without crossing into fetal circulation
Fetal Growth Restriction white paper authored by leading maternal-fetal medicine experts released

DiaMedica Therapeutics Announces First Patients Dosed in Phase 2 Trial of DM199 for the Treatment of Fetal Growth Restriction

Tue, 23 Jun 2026 08:30:00 -0400

First clinical evaluation of DM199 (rinvecalinase alfa) in fetal growth restriction, a leading cause of stillbirth with no approved pharmacologic treatment
DM199 is intended to improve maternal uterine artery blood flow to the placenta without crossing into fetal circulation
Fetal Growth Restriction white paper authored by leading maternal-fetal medicine experts released

DiaMedica Therapeutics Announces First Patients Dosed in Phase 2 Trial of DM199 for the Treatment of Fetal Growth Restriction

Tue, 23 Jun 2026 08:30:00 -0400

First clinical evaluation of DM199 (rinvecalinase alfa) in fetal growth restriction, a leading cause of stillbirth with no approved pharmacologic treatment
DM199 is intended to improve maternal uterine artery blood flow to the placenta without crossing into fetal circulation
Fetal Growth Restriction white paper authored by leading maternal-fetal medicine experts released

DIAMEDICA gets FDA feedback on DM199 preeclampsia nonclinical work

Tue, 16 Jun 2026 08:30:35 -0400

DiaMedica Therapeutics Inc. (NASDAQ: DMAC) said it received written feedback from the U.S. Food and Drug Administration regarding additional nonclinical data needed to support continued development of DM199 (rinvecalinase alfa) for the treatment of preeclampsia.

According to the company, the FDA indicated that a previously completed rat reproductive toxicity study may be acceptable to support a U.S. investigational new drug (IND) application, provided DiaMedica can demonstrate sufficient evidence of DM199 exposure and enzymatic activity throughout that study, as well as adequate pharmacologic effect in rats to support their use as an appropriate toxicology species.

In response, DiaMedica said it is initiating a

DIAMEDICA gets FDA feedback on DM199 preeclampsia nonclinical work

Tue, 16 Jun 2026 08:30:35 -0400

In response, DiaMedica said it is initiating a

DIAMEDICA gets FDA feedback on DM199 preeclampsia nonclinical work

Tue, 16 Jun 2026 08:30:35 -0400

In response, DiaMedica said it is initiating a

DIAMEDICA gets FDA feedback on DM199 preeclampsia nonclinical work

Tue, 16 Jun 2026 08:30:35 -0400

In response, DiaMedica said it is initiating a

DiaMedica Receives FDA Feedback on DM199 Preeclampsia Nonclinical Program